Cyclacel Pharma (CYCC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 4:05 PM EDTÂ - Oral fadraciclib demonstrated good tolerability with continuous dosing;Â anticipate entering Phase 2 POC stage in 2H 2022
         - Demonstrated evidence of target engagement for CDK2 and CDK9
         - Company to host R&D day in fall of 2022 to highlight data updates          for fadraciclib and CYC140 in solid tumor Phase 1/2 studies
         - Cash runway into 2H 2023 -
               - Conference call scheduled for August 10, 2022 at 4:30 pm... More
